Stramsen Biotech Valued at $19 Billion, Seeks Investment Partners

Got story updates? Submit your updates here. ›

Stramsen Biotech, a venture-backed plant-based biopharmaceutical company, has announced a $19 billion enterprise valuation conducted by an independent third-party appraisal firm. The company is seeking investment bank and law firm partners as it prepares to submit an IND package for a wound care drug candidate and expand its pipeline of 32 other drug candidates. Stramsen plans to create hundreds of jobs and boost economies in Houston, Texas and other U.S. biotech hubs.

Why it matters

Stramsen Biotech's high valuation and ambitious growth plans highlight the increasing demand and investment in plant-based and natural medicines, as well as the potential for the company to drive innovation and economic activity in the life sciences sector.

The details

Stramsen Biotech's $19 billion valuation was determined by Stonebridge Advisory Inc. based on factors like the company's strong brand, FDA progress, expert management, financial forecasts, and market opportunity. The company has reserved the trading symbol SBRX and is awaiting final FDA comments before submitting an IND package for its wound care drug candidate SBX-1977. Stramsen is seeking partnerships with investment banks and law firms of all sizes as it looks to raise capital and expand its operations.

• Stramsen Biotech's enterprise valuation was conducted on February 18, 2026.
• The company is awaiting final FDA comments before submitting its IND package.

What’s next

Stramsen Biotech is awaiting final FDA comments before submitting the complete IND Package for its woundcare drug candidate SBX-1977.